Page 126 - Read Online

Page 12 of 12 Feuer et al. J Cancer Metastasis Treat 2021;7:68 https://dx.doi.org/10.20517/2394-4722.2021.164

34. Gershman B, Thompson RH, Moreira DM, et al. Radical nephrectomy with or without lymph node dissection for nonmetastatic renal
cell carcinoma: a propensity score-based analysis. Eur Urol 2017;71:560-7. DOI PubMed
35. John NT, Blum KA, Hakimi AA. Role of lymph node dissection in renal cell cancer. Urol Oncol 2019;37:187-92. DOI PubMed
36. Ouzaid I, Capitanio U, Staehler M, et al; Young Academic Urologists Kidney Cancer Working Group of the European Association of
Urology. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol 2019;2:141-9. DOI PubMed
37. Ishihara H, Takagi T, Kondo T, et al. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era.
Urol Oncol 2021;39:77.e17-25. DOI PubMed
38. Takagi T, Fukuda H, Ishihara H, et al. Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal
cell carcinoma in the targeted therapy era. Urol Oncol 2020;38:515-20. DOI PubMed
39. Palumbo C, Pecoraro A, Knipper S, et al. Survival and complication rates of metastasectomy in patients with metastatic renal cell
carcinoma treated exclusively with targeted therapy: a combined population-based analysis. Anticancer Res 2019;39:4357-61. DOI
PubMed
40. Meyer CP, Sun M, Karam JA, et al. Complications after metastasectomy for renal cell carcinoma-a population-based assessment. Eur
Urol 2017;72:171-4. DOI PubMed
41. Karam JA, Rini BI, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol
2011;185:439-44. DOI PubMed PMC
42. Li JR, Ou YC, Yang CK, et al. The impact of local intervention combined with targeted therapy on metastatic renal cell carcinoma.
Anticancer Res 2018;38:5339-45. DOI PubMed
43. Procopio G, Apollonio G, Cognetti F, et al. Sorafenib versus observation following radical metastasectomy for clear-cell renal cell
carcinoma: results from the phase 2 randomized open-label RESORT study. Eur Urol Oncol 2019;2:699-707. DOI PubMed
44. Appleman LJ, Puligandla M, Pal SK, et al. Randomized, double-blind phase III study of pazopanib versus placebo in patients with
metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: a trial of the ECOG-ACRIN cancer
research group (E2810). J Clin Oncol 2019;37:4502. DOI
45. Rausch S, Gouttefangeas C, Hennenlotter J, et al. Results of a phase 1/2 study in metastatic renal cell carcinoma patients treated with a
patient-specific adjuvant multi-peptide vaccine after resection of metastases. Eur Urol Focus 2019;5:604-7. DOI PubMed
46. Ishihara H, Takagi T, Kondo T, Fukuda H, Yoshida K, Tanabe K. Nivolumab treatment beyond progression for metastatic renal cell
carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era? Int J Urol 2020;27:691-2. DOI PubMed
47. Dragomir A, Nazha S, Wood LA, et al. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The
Canadian Kidney Cancer information system experience. Urol Oncol 2020;38:799.e1-799.e10. DOI PubMed
48. Lyon TD, Thompson RH, Shah PH, et al. Complete surgical metastasectomy of renal cell carcinoma in the post-cytokine era. J Urol
2020;203:275-82. DOI PubMed
49. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone
for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9. DOI PubMed
50. Mickisch G, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy
compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70. DOI PubMed
51. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med
2018;379:417-27. DOI PubMed
52. Massari F, Di Nunno V, Gatto L, et al. Should CARMENA really change our attitude towards cytoreductive nephrectomy in metastatic
renal cell carcinoma? Target Oncol 2018;13:705-14. DOI PubMed
53. Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous
metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 2019;5:164-70. DOI
PubMed PMC
54. Bhindi B, Abel EJ, Albiges L, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and
beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol 2019;75:111-28. DOI PubMed
55. Gao J, Karam JA, Tannir NM, et al. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo +
ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN),
metastasectomy (MS) or posttreatment biopsy (Bx). J Clin Oncol 2018;36:4520. DOI
56. Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma
in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urol Oncol 2020;38:604.e9-604.e17. DOI
PubMed PMC
57. Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic
disease. Cancer Discov 2016;6:1382-99. DOI PubMed
58. Clark DJ, Dhanasekaran SM, Petralia F, et al; Clinical Proteomic Tumor Analysis Consortium. Integrated proteogenomic
characterization of clear cell renal cell carcinoma. Cell 2020;180:207. DOI PubMed
59. Ricketts CJ, Linehan WM. Intratumoral heterogeneity in kidney cancer. Nat Genet 2014;46:214-5. DOI PubMed PMC
60. Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Science 2018;359:801-6. DOI PubMed PMC
61. Verbiest A, Couchy G, Job S, et al. Molecular subtypes of clear-cell renal cell carcinoma are prognostic for outcome after complete
metastasectomy. Eur Urol 2018;74:474-80. DOI PubMed
62. Patel HD, Puligandla M, Shuch BM, et al. The future of perioperative therapy in advanced renal cell carcinoma: how can we
PROSPER? Future Oncol 2019;15:1683-95. DOI PubMed PMC